Anti-Human PCSK9 Recombinant Antibody (SAA2543) (HV275033)

Name: Anti-Human PCSK9 Recombinant Antibody (SAA2543)
Brand: abinScience
SKU: HV275033
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HV275033

Reactividad de especies

Human

Aplicaciones

ELISA

Clonalidad

Monoclonal

Isotipo

scFv-His

ID de clon

SAA2543

Objetivo

EC:3.4.21.-, NARC-1, NARC1, Neural apoptosis-regulated convertase 1, PC9, PCSK9, Proprotein convertase 9, Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Purified by Nickel column.

Número de acceso

Q8NBP7

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).

1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658

2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796

3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702

4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458

5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827

6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751

Nota

For research use only

Imágenes